Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

INTRODUCTION: Most patients with type 2 diabetes require sequential addition of glucose-lowering agents to maintain long-term glycemic control. In this retrospective, observational study, we compared intensification with a glucagon-like peptide-1 receptor agonist (GLP-1 RA), oral antidiabetic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Desouza, Cyrus, Kirk, Andreas R, Mangla, Kamal K, Wolden, Michael L, Lingvay, Ildiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Emerging Technologies, Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778743/
https://www.ncbi.nlm.nih.gov/pubmed/33376084
http://dx.doi.org/10.1136/bmjdrc-2020-001830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778743/
https://www.ncbi.nlm.nih.gov/pubmed/33376084
http://dx.doi.org/10.1136/bmjdrc-2020-001830

Ejemplares similares